BIO's solution to drug benefit

While the Clinton administration and the Democratic leadership will be leaning on procedure and power to push the health care bill through, the industry's advocates in Washington haven't given up on the power of persuasion.

The Biotechnology Industry Organization plans a strong pitch for a proposal, which hasn't been finalized yet, that would obviate the need for the Medicare rebate and blacklist by putting the plan's drug benefit into the private sector.